Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) - USD ($)					1 Months Ended				3 Months Ended		6 Months Ended
	Jun. 06, 2017	Jan. 09, 2017	Aug. 04, 2016	Feb. 27, 2014	Sep. 30, 2016	Aug. 31, 2016	Jul. 24, 2012	Jun. 15, 2012	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Feb. 16, 2016
Commitments and Contingencies (Textual)
License fee payment											$ 7,529
Research recorded fees									$ 4,379,047	$ 4,147,945	8,883,398	$ 7,913,397
Cost of lease agreement	$ 312,660					$ 2,400
Accounts payable and accrued expenses									3,604,579		3,604,579		$ 4,194,874
Lease term	7 years 3 months
Lease agreements, Description	The first 4 years, and an annual rate of $341,610 for the remaining period.
Lines of credit											390,825
Deposit									390,825		390,825
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost				$ 6,800,000							2,500,000
Non - refundable institutional fee				$ 600,000
Total project estimated to cost									100,000		100,000		$ 100,000
Research and development costs											300,000	200,000
CRO Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost			$ 4,600,000								200,000
AbbVie Biotherapeutics Corp [Member]
Commitments and Contingencies (Textual)
Milestones Payments											7,750,000
AbbVie Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment											3,000,000
Milestones Payments											$ 7,750,000
Description of royalty payment											The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage											12.00%
First commercial sale period											12 years 6 months
AbbVie Biotherapeutics Corp [Member] \| After first net sales [Member]
Commitments and Contingencies (Textual)
Milestones Payments											$ 1,500,000
AbbVie Biotherapeutics Corp [Member] \| Phase 1 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones Payments							$ 750,000				750,000
Accounts payable and accrued expenses									750,000		750,000
AbbVie Biotherapeutics Corp [Member] \| Phase 2 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones Payments											750,000
Research and development costs					$ 750,000
Abbott Biotherapeutics Corp [Member] \| After first net sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment											10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs		$ 700,000									$ 300,000	300,000
Icon Clinical Research [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage											12.50%
Down payment for project											$ 1,900,000
Down payment paid in 2007 and 2012											200,000
Total project estimated to cost									$ 2,700,000		2,700,000
Research and development costs											0	300,000
Fred Hutchinson Cancer Research Center [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones Payments								$ 1,000,000
Description of royalty payment								Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )								$ 200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )								300,000
Research recorded fees											44,000	400,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration								23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| License and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration								$ 13,200,000
Medpace, Inc. [Member] \| CRO Agreement [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost														$ 7,200,000
Research and development costs											$ 1,400,000	$ 1,600,000